By Anna Sheinman, February 1, 2013
Results of the first clinical trial for a new cancer vaccine developed by an Israeli company suggest it could “change the paradigm” of cancer treatment, the head researcher has said.
Dr Lior Carmon, CEO of Vaxil, based near Tel Aviv, said that the results of the phase I trial of the vaccine on 15 cancer patients with multiple myeloma, a blood cancer, were very promising.
More..